Innovative Visionary Mark W Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina s Growth Vision balticbusinessnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from balticbusinessnews.com Daily Mail and Mail on Sunday newspapers.
Management expressed positive long-term outlook for the sector and expressed confidence in Syngene s sustained performance on the back of improved fund flows into US biotech in the latter part of the year.
Innovative Visionary Mark W Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina s Growth Vision australiannews.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from australiannews.net Daily Mail and Mail on Sunday newspapers.
Before switching to the listing route, TPG-backed Sai Life Sciences had explored the sale of a controlling stake in the firm and conducted a sale process, which resulted in Bain Capital emerging as the front-runner in the final leg, according to a January 25 report by Moneycontrol. But talks between both parties did not fructify into a deal
The rise in Q3 profit of Syngene International was led by dedicated centres and development and manufacturing services, even as discovery services business remained soft. The third quarter revenue from operations rose 9% YoY to Rs. 854 crore. The earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 5% YoY to Rs. 261 crore in Q3FY24. The EBITDA margin dropped 100 basis points YoY to 30%.